Slide Deck 4: Natural Products and Derivatives

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/23

encourage image

There's no tags or description

Looks like no tags are added yet.

24 Terms

1
New cards

Major Therapeutic Classes of Natural Products Used in Oncology

  1. Anti-mitotic Agents

    1. Microtubule stabilizers

      1. _____

      2. _____

    2. Microtubule destabilizers

      1. _____ _____

  2. Topoisomerase Inhibitors

    1. ______

    2. ______

  3. Antitumor antibiotics

    1. ______ (also classified as topo inhibitors)

    2. ______


  1. Anti-mitotic Agents

    1. Microtubule stabilizers

      1. Epothilones

      2. Taxanes

    2. Microtubule destabilizers

      1. Vinca Alkaloids

  2. Topoisomerase Inhibitors

    1. Camptothecins (topo 1)

    2. Podophyllotoxins (topo 2)

  3. Antitumor antibiotics

    1. Anthracyclines (also classified as topo 2 inhibitors)

    2. Bleomycins


2
New cards

Anti-tumor Antibiotics: Anthracyclines

  1. What species are these antibiotics isolated from?

  2. List the 4 anthracyclines.

  3. What is the MOA?


  1. streptomyces

  2. doxorubicin (DOX), daunorubicin (DNR), idarubicin (IDA), epirubicin (EPI)

  3. inhibit topoisomerase II class of enzymes


3
New cards

Anthracyclines MOA:

Doxorubicin (Adriamycin)

  • widely used; broad-spectrum

  • How does DOX cause apoptosis of cancer cells (3 ways)?

  • What color is DOX?

  • What will happen if DOX is extravasated? How does this affect administration?


  • intercalation into DNA, generation of ROS (reactive oxygen species), Topoisomerase IIa inhibition

  • Red - “red devil”

  • It can cause severe local tissue necrosis; means that it can never be given intramuscularly or subcutaneously


4
New cards

Doxorubicin Adverse Events

Cardiotoxicity is ____.

  • as a result of dox and iron interacting and forming ROS

What is the lifetime maximum cumulative dose of DOX?


cumulative (dose-dependent decline in mitochondrial oxidative phosphorylation)

  • topoisomerase 2B is the key mediator of anthracycline-induced cardiotoxicity


550 mg/m2

  • low dose = reversible damage. high dose = irreversible heart damage


5
New cards

Mitigation of Anthracycline-Mediated Cardiotoxicity

At what cumulative dose of DOX is a medicine given to prevent toxicity, and what is the drug/MOA?

300 mg/m2; dexrazoxane (Zinecard, DRZ) —> MOA: chelates iron and blocks iron-mediated free ROS generation; out-competes anthracyclines for topo 2b inhibition (expressed in cardiomyocytes)

6
New cards

Is doxorubicin available with liposomes? If so, why?

Yes, and it is called DOXIL. The fat bubble coating allows DOXIL to evade destruction by the immune system and increases the amount of time drug is in the body. The majority of the drug stays inside the liposome while in the blood, so DOXIL has more time to reach the tumor tissue.

Administration: IV infusion

Same BW and max doses

7
New cards

Antitumor Antibiotics: Bleomycins (glycopeptide)

  • From Streptomyces

  • True or false: Is this apart of the ABVD regimen?


Yes

•Consist of a metal binding, DNA binding, and carbohydrate domain.

8
New cards

Bleomycins

What is the MOA of bleomycins? What is the most severe adverse event?

  1. They bind metals iron or copper and oxygen and can catalyze formation of single-stranded (ss) and double-strand (ds) DNA breaks

  • damage is similar to that generated by ionizing radiation

  1. Bleomycin Pulmonary Toxicity (BPT): lung inflammation proceeds to lung fibrosis


9
New cards

Not a question.

Topoisomerase is an enzyme that works in front of the replication fork.

Introduces nicks in the DNA backbone allowing the rotation of one strand around the other. —> releases the torsional strain which would otherwise accumulate in front of the advancing replication fork

Topoisomerase Inhibitors: prevent this process; several FDA approved anticancer drugs are classified as topo inhibitors

10
New cards

Which drug is a human topoisomerase 1 inhibitor that is S-phase specific and a prodrug?

  • also indicated for metastatic colorectal cancer


Camptosar (Irinotecan)

  • prevents topo-I mediated re-ligation of the DNA, resulting in dsDNA breaks and induction of apoptosis


11
New cards

What enzyme is crucial for the metabolism of irinotecan?

UGT1A1

<p>UGT1A1</p>
12
New cards

Unlike doxorubicin, dose related AEs ARE REVERSIBLE. Anyways, what are the two black box warnings of irinotecan? These adverse events are associated with high exposure of ____ and defects in ____.

Severe myelosuppression and severe diarrhea; SN-38 and UGT1A1

  • •Non-functional UGT1A1 alters metabolism of SN-38---simulated overdose.

    •Problem with homozygous *28 allele  


13
New cards

Topo II Inhibitors

What are the two topo II inhibitors and what are they derivatives of?

Etoposide and teniposide; pdophyllotoxin (anti-tubulin drug)

14
New cards

Antimitotic Agents: General

Not a question.


15
New cards

Antimitotic Agents and Tubulin-Microtubule Dynamics

Not a question.

Microtubules: alpha and beta tubulin subunits that form hollow, cylindrical structures

Role: cell machinery, cell growth/division/motility

Dynamic equilibrium: binding of tubulin dimers to a growing MT and subsequent de-polymerization back to tubulin dimers (GTP dependent)

Generate: mitotic spindle (segregate chromosomes correctly during cell division)

16
New cards

Microtubule Destabilizers - Vinca Alkaloids

What are the two microtubule destabilizers? How do they destabilize?

  1. Vincristine (Oncovin) [vincristine sulfate liposome injection - MARQIBO]

  2. Vinblastine (Velban)


Vinca alkaloids arrest the cell cycle in metaphase by a fast and reversible binding to the beta-tubulin subunit in a region called the Vinca domain. They prevent assembly into microtubules, thus are termed microtubule destabilizers.

17
New cards

MARQIBO - Vincristine Sulfate Liposome Injection

  1. What is the formulation?

  2. What are the benefits over regular vincristine?

  3. Indication?

  4. Administration?


  1. Nanoparticle-encapsulated formulation: optisome technology

  2. less toxicity, more effective

  3. ALL (Philadelphia chromosome negative)

  4. IV only (different dosing than regular vincristine)


18
New cards

Anti-mitotic agents: Microtubulin Stabilizers

  1. Two Major Classes

    1. Taxanes

      1. Paclitaxel _____

      2. Docetaxel _____

      3. Cabazitaxel ____

    2. Epothilones

      1. Ixabepilone _____


  1. Two Major Classes

    1. Taxanes

      1. Paclitaxel (Taxol) [1st in class]

        1. Paclitaxel-albumin formulation (Abraxane)

      2. Docetaxel (Taxotere)

      3. Cabazitaxel (Jevtana)

    2. Epothilones

      1. Ixabepilone (Ixembpra)


19
New cards

Taxanes

How do taxanes stabilize microtubules?

Bind to a pocket in beta-tubulin: prevents depolymerization of microtubules

20
New cards

Taxanes

What are 3 major toxicities associated with taxanes?

  1. Myelosuppression

  2. Peripheral neuropathy

  3. Hypersensitivity


side effects are increased when these drugs are prescribed in combo with other medicines like platinum agents and doxorubicin


21
New cards

This medication eliminates the need for premedication with steroids/antihistamines for hypersensitivity reactions from taxanes.

Abraxane (Nab-paclitaxel)

  • uses albumin to deliver chemo

  • administered in 30 minutes


22
New cards

Compare the adverse effects of taxanes (drug-specific).

  • Paclitaxel

  • Docetaxel

  • Cabazitaxel

  • Nab-paclitaxel


  • Paclitaxel (BAND)

    • bradycardia, alopecia, nail discoloration, derm effects

  • Docetaxel (FSS)

    • stomatitis, skin toxicities, fluid retention

  • Cabazitaxel (CINVD)

    • Constipation, infections, nausea, vomiting, diarrhea

  • Nab-paclitaxel (VEMAN)

    • Vomiting, elevated LFTs, myalgia, alopecia, nausea


23
New cards

Ixabepilone (Ixempra) has the same MOA of paclitaxel (stabilizing MTs and inducing apoptosis). When is this drug used and what is its benefit over taxanes?

  1. In locally advanced breast cancer patients after a failure of a anthracycline and a taxane IN COMBO WITH CAPECITABINE

  2. as monotherapy for metastatic/locally advanced breast cancer in patients after failing an anthracycline, taxne, and capecitabine


Benefits over taxanes: possesses low susceptibility to tumor resistance mechanisms including efflux transporters, such as MRP-1 and P-glycoprotein (P-gp). 


24
New cards

Not a question.

knowt flashcard image